An Updated Review of ISCOMSTM and ISCOMATRIXTM Vaccines
Overview
Authors
Affiliations
The need for the improvement of vaccine potency as well as reducing toxicity in healthy recipients has motivated studies of the formulation of vaccines regarding control of how, when, and where antigens and adjuvants encounter immune cells and other cells/tissues following vaccine administration. Immunostimulatory complexes (ISCOMs) and ISCOMATRIXTM adjuvants are versatile and flexible systems with various phospholipids and saponin components. They are being used in novel vaccines for either infectious diseases or cancer. This article presents a brief review of the latest developments using such adjuvants and possible new applications.
The quest for nanoparticle-powered vaccines in cancer immunotherapy.
Sun Z, Zhao H, Ma L, Shi Y, Ji M, Sun X J Nanobiotechnology. 2024; 22(1):61.
PMID: 38355548 PMC: 10865557. DOI: 10.1186/s12951-024-02311-z.
Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens.
Dotiwala F, Upadhyay A Vaccines (Basel). 2023; 11(10).
PMID: 37896988 PMC: 10611113. DOI: 10.3390/vaccines11101585.
The Matrix-M™ adjuvant: A critical component of vaccines for the 21 century.
Stertman L, Palm A, Zarnegar B, Carow B, Lunderius Andersson C, Magnusson S Hum Vaccin Immunother. 2023; 19(1):2189885.
PMID: 37113023 PMC: 10158541. DOI: 10.1080/21645515.2023.2189885.
Emerging concepts in the science of vaccine adjuvants.
Pulendran B, Arunachalam P, OHagan D Nat Rev Drug Discov. 2021; 20(6):454-475.
PMID: 33824489 PMC: 8023785. DOI: 10.1038/s41573-021-00163-y.
Saponins from and : Particular Chemical Characteristics and Biological Activities.
Fleck J, Betti A, da Silva F, Troian E, Olivaro C, Ferreira F Molecules. 2019; 24(1).
PMID: 30621160 PMC: 6337100. DOI: 10.3390/molecules24010171.